Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Average common stock and common equivalent shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Domestic Tax Authority Income Tax Jurisdiction, Domestic Federal [Member] Title of 12(b) security Title of 12(b) Security Carrying Amount Reported Value Measurement [Member] Document fiscal year focus Document Fiscal Year Focus Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Transaction-related costs Business Combination, Acquisition-Related Cost, Expense Total stock-based compensation expense, net of income taxes Share-Based Payment Arrangement, Expense, after Tax Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Apple Inc. vs. Masimo Apple Inc. vs. Masimo [Member] Apple Inc. vs. Masimo Common stock - $0.01 par value, 2.0 billion shares authorized; 888.2 million issued and 702.9 million outstanding as of June 26, 2026; 886.9 million issued and 706.9 million outstanding as of December 31, 2025 Common Stock, Value, Issued Components of Debt Schedule of Long-Term Debt Instruments [Table Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Line of credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Proceeds from sales of investments Proceeds from Sale, Maturity and Collection of Investments Derivative Instrument [Axis] Derivative Instrument [Axis] Income tax impact Other Comprehensive Income (Loss) before Reclassifications, Tax U.S. dollar-denominated commercial paper US Dollar-Denominated Commercial Paper [Member] US Dollar Denominated Commercial Paper [Member] 0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) 0.65% Senior Notes Due 2032 [Member] 0.65% Senior Notes Due 2032 [Member] Amendment flag Amendment Flag Goodwill [Line Items] Goodwill [Line Items] Current liabilities: Liabilities, Current [Abstract] Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] 2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”) 2.6% Senior Unsecured Notes Due 2050 [Member] 2.6% Senior Unsecured Notes Due 2050 Entity common stock, shares outstanding Entity Common Stock, Shares Outstanding Property, plant and equipment Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment Loss Contingencies [Table] Loss Contingencies [Table] Common stock issued in connection with acquisitions Stock Issued During Period, Value, Acquisitions Business Combination, Pro Forma Information, Nonrecurring Adjustment [Axis] Business Combination, Pro Forma Information, Nonrecurring Adjustment [Axis] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity address, state Entity Address, State or Province PEO Total Compensation Amount PEO Total Compensation Amount Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Assets: Assets, Fair Value Disclosure [Abstract] Capital expenditures Segment Reporting, Long-Lived Asset, Expenditure for Addition Other intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Share Repurchase Program [Domain] Share Repurchase Program [Domain] Derivative, notional amount outstanding Derivative, Notional Amount Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Basic (in shares) Weighted average common shares outstanding used in Basic EPS (in shares) Weighted Average Number of Shares Outstanding, Basic Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Work in process Inventory, Work in Process, Net of Reserves 3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”) 3.25% Senior Unsecured Notes Due 2039 [Member] 3.25% Senior Unsecured Notes Due 2039 [Member] 2.38% senior unsecured bonds due 6/3/2041 (CHF 648 million) (the “2041 CHF Bonds”) 1.94% 2045 CHF Notes [Member] 1.94% 2045 CHF Notes Entity address, city Entity Address, City or Town Pending Litigation Pending Litigation [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Class of Stock [Axis] Class of Stock [Axis] Finite-lived intangible assets, net Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Inventories: Inventory, Net [Abstract] 1.200% Senior Notes due 2027 1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) 1.2% Senior Notes Due 2027 [Member] 1.2% Senior Notes Due 2027 [Member] Proposed adjustments to taxable income, self-insurance, other Income Tax Examination, Self-insurance Programs, Proposed Adjustments to Taxable Income Income Tax Examination, Self-insurance Programs, Proposed Adjustments to Taxable Income Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Nonoperating income (expense): Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Line of credit facility Line of Credit Facility, Maximum Borrowing Capacity Total other comprehensive income (loss), net of income taxes Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Proceeds from sale of product line Proceeds from sale of product line Proceeds From Sale Of Product Line Proceeds From Sale Of Product Line Cash flow hedge adjustments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Standards Recently Adopted and Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Segment Results Segment Reporting [Table Text Block] Noncontrolling interests Noncontrolling Interest [Member] Investment gains (losses): Gain (Loss) on Investments [Abstract] Less: Segment Reporting, Reconciliation [Abstract] Subtotal Borrowings outstanding Long-Term Debt Employment agreement, severance benefit, cash payment Employment Agreement, Severance Benefit, Cash Payment Employment Agreement, Severance Benefit, Cash Payment Masimo Corporation Masimo Masimo Corporation Acquisition [Member] Masimo Corporation Acquisition Proceeds from debt, net of issuance costs Proceeds from Debt, Net of Issuance Costs Document period end date Document Period End Date Total cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Aggregate principal amount Debt Instrument, Face Amount 2.38% senior unsecured bonds due 6/3/2041 (CHF 648 million) (the “2041 CHF Bonds”) 4.375% Senior Notes Due 2045 [Member] 4.375% Senior Unsecured Notes Due 2045 [Member] Operating costs: Costs and Expenses [Abstract] Security exchange name Security Exchange Name Debt term Debt Instrument, Term Change in noncontrolling interests Noncontrolling Interest, Period Increase (Decrease) Treasury stock Treasury Stock, Common, Value Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity shell company Entity Shell Company Consolidation Items [Domain] Consolidation Items [Domain] 2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”) 2.8% Senior Unsecured Notes Due 2051 [Member] 2.8% Senior Unsecured Notes Due 2051 Long-term Tax Liabilities Tax Liabilities, Noncurrent, Policy [Policy Text Block] Tax Liabilities, Noncurrent, Policy Recurring revenue Revenue from Contract with Customer, Measurement, Recurring [Member] Revenue from Contract with Customer, Measurement, Recurring [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Net Earnings Per Common Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Biotechnology Biotechnology Segment [Member] Biotechnology Segment Net earnings per common share: Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document fiscal period focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Trading symbol Trading Symbol 1.88% senior unsecured bonds due 6/3/2033 (CHF 137 million) (the “2033 CHF Bonds II”) 2033 CHF Notes II 1.88% Senior Notes Due June 2033 CHF Notes II [Member] 1.88% Senior Notes Due June 2033 CHF Notes II Geographical [Domain] Geographical [Domain] Payments for additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Executive Employment Agreement Executive Employment Agreement [Member] Executive Employment Agreement Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Reporting Units-Total Reporting Units-Total [Member] Reporting Units-Total Fair Values of the Assets Acquired and Liabilities Assumed Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Company Selected Measure Name Company Selected Measure Name Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Incremental common shares from: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] 1.6249% senior unsecured bonds due 10/9/2037 (CHF 225 million) (the “2037 CHF Bonds”) 1.6249% Senior Notes Due October 2037 [Member] 1.6249% Senior Notes Due October 2037 Pension and Postretirement Plan Benefit Adjustments Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Western Europe Western Europe [Member] Western Europe [Member] 2038 Euronotes 4.000% senior unsecured notes due 4/29/2038 (€1.0 billion) the (“2038 Euronotes”) 4.000% Senior Notes Due April 2038 Euro Notes [Member] 4.000% Senior Notes Due April 2038 Euro Notes Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Credit Facility [Domain] Credit Facility [Domain] 3.250% Senior Notes due 2030 3.250% senior unsecured notes due 4/29/2030 (€750 million) (the “2030 Euronotes II”) 2030 Euronotes II 3.250% Senior Notes Due April 2030 Euro Notes II [Member] 3.250% Senior Notes Due April 2030 Euro Notes II Consideration for pre-acquisition service Less non-cash consideration Business Combination, Consideration Transferred, Tangible and Intangible Assets, Excluding Cash Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Revenue reported by acquired entity for last annual period (approximately) Business Combination, Acquiree's Revenue, Prior Period Balance, beginning of period Balance, end of period Shares, Issued Business Combination, Nonrecurring Adjustment, Transaction Costs Business Combination, Nonrecurring Adjustment, Transaction Costs [Member] Business Combination, Nonrecurring Adjustment, Transaction Costs Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Diluted (in shares) Weighted average common shares outstanding used in Diluted EPS (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity emerging growth company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial paper Commercial Paper [Member] Hedging Transactions and Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Cover Page [Table] Entities [Table] 2024 and 2025 Repurchase Program 2024 And 2025 Repurchase Program [Member] 2024 And 2025 Repurchase Program Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Gross profit Gross Profit Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Award Timing Predetermined Award Timing Predetermined [Flag] Treasury stock Treasury Stock, Common [Member] Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Quoted Prices in Active Market (Level 1) Fair Value, Inputs, Level 1 [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Intangible Asset, Indefinite-Lived, Class [Domain] Intangible Asset, Indefinite-Lived, Class [Domain] Litigation Status [Domain] Litigation Status [Domain] Assumed exercise of dilutive options and vesting of dilutive restricted stock units (“RSUs”) and performance stock units (“PSUs”) (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Revenues from divested product line Disposal Group, Not Discontinued Operation, Certain Product Lines, Revenues Disposal Group, Not Discontinued Operation, Certain Product Lines, Revenues All Executive Categories All Executive Categories [Member] Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Other comprehensive income (loss), net of income taxes: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Long-term debt Long-Term Debt, Fair Value Depreciation Depreciation Depreciation Reporting Unit, Change In Businesses Reporting Unit, Change In Business [Member] Reporting Unit, Change In Business Operating lease, right-of-use assets Operating Lease, Right-of-Use Asset AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Life Sciences Life Sciences [Member] Life Sciences [Member] Total Masimo Financing CHF Notes Masimo Financing CHF Notes [Member] Masimo Financing CHF Notes Information Related to the Calculation of Net Earnings Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Net assets acquired Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Segment Information Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Hedging Relationship [Axis] Hedging Relationship [Axis] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Effect of exchange rate changes on cash and equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Diluted EPS (in usd per share) Income (Loss) from Continuing Operations, Per Diluted Share Basic EPS (in usd per share) Income (Loss) from Continuing Operations, Per Basic Share Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Total stockholders’ equity Balance, beginning of period Balance, end of period Equity, Including Portion Attributable to Noncontrolling Interest Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Facility Building [Member] Number of patents found Infringed Loss Contingency, Patents Found Infringed, Number Business Combination [Line Items] Business Combination [Line Items] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Numerator Earnings Per Share Reconciliation [Abstract] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Trade accounts receivable Business Combination, Recognized Asset Acquired, Receivable, Current Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Investment losses and pretax gain on sale of product line Investment (Gains) Losses And Pretax Gain On Sale Of Product Line Investment (Gains) Losses And Pretax Gain On Sale Of Product Line 0.8875% senior unsecured bonds due 10/10/2029 (CHF 325 million) (the “2029 CHF Bonds”) 0.8875% 2029 CHF Notes [Member] 0.8875% 2029 CHF Notes Exercise Price Award Exercise Price Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Litigation Status [Axis] Litigation Status [Axis] Segment Reporting [Line Items] Segment Reporting [Line Items] Original Notional Amount Derivative and Nonderivative, Original Notional Amount Derivative and Nonderivative, Original Notional Amount Pro Forma net earnings Net earnings Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document quarterly report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Interest rate swaps Interest Rate Swap [Member] Financing Debt Disclosure [Text Block] Debt discounts, premiums and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity method investments Equity Method Investments Business Combination [Table] Business Combination [Table] Equity Component [Domain] Equity Component [Domain] Masimo vs. Apple Inc. Masimo vs. Apple Inc. [Member] Masimo vs. Apple Inc. PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Trade accounts payable Accounts Payable, Trade, Current Cross-currency contracts Foreign Exchange Contract [Member] Cross-currency swap derivative contracts Foreign Currency Contract, Asset, Fair Value Disclosure Adoption Date Trading Arrangement Adoption Date Schedule of Other Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] OCI before reclassifications: Other Comprehensive Income (Loss), before Tax Period Change [Abstract] Partnership Partnership [Member] Interest rate of debt instrument Stated Annual Interest Rate Debt Instrument, Interest Rate, Stated Percentage Common stock dividends declared Dividends, Common Stock, Cash Total Danaher stockholders’ equity Equity, Attributable to Parent Repayments of borrowings (maturities longer than 90 days) Repayments of Debt, Maturing in More than Three Months Nonderivative, notional amount Nonderivative hedging instruments Notional Amount of Nonderivative Instruments ASSETS Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Operating lease, liabilities Operating Lease, Liability Insider Trading Policies and Procedures [Line Items] All other financing activities Proceeds from (Payment for) Other Financing Activity Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Damages awarded by jury verdict Loss Contingency, Damages Awarded, Value Number of shares of Company common stock approved for repurchase (in shares) Share Repurchase Program, Authorized, Number of Shares Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Selling, general and administrative expenses Selling, General and Administrative Expense 1.265% senior unsecured bonds due 10/10/2033 (CHF 325 million) (the “2033 CHF Bonds”) 1.265% Senior Notes Due October 2033 [Member] 1.265% Senior Notes Due October 2033 Business Combination [Domain] Business Combination [Domain] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount RSU/PSUs Restricted Stock Units (RSUs) [Member] Nonrecurring fair value adjustments to inventory, settlement of pre-acquisition share-based payment awards and change in control payments Business Combination, Nonrecurring Adjustment, Inventory, Fair Value Adjustment, Settlement Of Pre-acquisition Share-Based Payment Awards And Other Compensation Payments [Member] Business Combination, Nonrecurring Adjustment, Inventory, Fair Value Adjustment, Settlement Of Pre-acquisition Share-Based Payment Awards And Other Compensation Payments Rollforward of Goodwill Goodwill by Segment Goodwill [Table Text Block] Reclassification adjustments: Reclassification from AOCI, Current Period [Abstract] Reclassification from AOCI, Current Period Entity central index key Entity Central Index Key Property, plant and equipment, accumulated depreciation Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Business Combination [Axis] Business Combination [Axis] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Gain on sale of product line, net of tax Gain (Loss) On Sale of Product Lines, Net of Tax Gain (Loss) On Sale of Product Lines, Net of Tax 2.100% Senior Notes due 2026 2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) 2.1% Senior Notes Due 2026 [Member] 2.1% Senior Notes Due 2026 [Member] 2.51% senior unsecured bonds due 6/3/2046 (CHF 502 million) (the 2046 CHF Bonds”) 2046 CHF Notes 2.51% Senior Notes Due June 2046 [Member] 2.51% Senior Notes Due June 2046 Revenue, remaining performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage High-growth markets High-Growth Markets [Member] The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which includes Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). OCI before reclassifications, net of income taxes Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Income Statement [Abstract] Income Statement [Abstract] Document transition report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Total investment gains (losses) Gain (Loss) on Investments Share Repurchase Program [Table] Share Repurchase Program [Table] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Diluted net earnings per common share (in usd per share) Business Combination, Pro Forma Information, Pro Forma Earnings Per Share, Diluted Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Other Other [Member] Other [Member] City area code City Area Code Variable Rate [Domain] Variable Rate [Domain] Other developed markets Other Developed Markets [Member] Other developed markets [Member] Accumulated other comprehensive income (loss) Accumulated Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Floating Rate Senior Notes due 2028 Floating rate senior unsecured notes due 4/29/2028 (€500 million) (the “2028 Floating Rate Notes”) 2028 Floating Rate Notes Floating Rate Senior Notes Due 2028 [Member] Floating Rate Senior Notes Due 2028 All Individuals All Individuals [Member] Payment of dividends Payments of Dividends Name Forgone Recovery, Individual Name Finished goods Inventory, Finished Goods, Net of Reserves Weighted average period for cost to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Statement [Line Items] Statement [Line Items] Total assets Identifiable assets Assets Business Combination [Abstract] Business Combination [Abstract] Debt Rate, Condition One Debt Rate, Condition One [Member] Debt Rate, Condition One Nonrecurring revenue Revenue from Contract with Customer, Measurement, Nonrecurring [Member] Revenue from Contract with Customer, Measurement, Nonrecurring [Member] Common shares reserved for issuance under the 2007 Omnibus Incentive Plan (in shares) Common Stock, Capital Shares Reserved for Future Issuance Operating segments Operating Segments [Member] Interest expense Interest Expense, Nonoperating Stockholders' Equity and Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Increase (decrease) Other Comprehensive Income (Loss), before Reclassifications, before Tax PEO PEO [Member] Pretax compensation expense Share-Based Payment Arrangement, Expense Measurement Basis [Axis] Measurement Basis [Axis] Other long-term liabilities Other Liabilities, Noncurrent Goodwill Balance, beginning of period Balance, end of period Total goodwill Goodwill Inventories Business Combination, Recognized Asset Acquired, Inventory, Current Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Attributable to the 2026 acquisition Goodwill, Acquired During Period Reporting Unit [Axis] Reporting Unit [Axis] Trade accounts payable Business Combination, Recognized Liability Assumed, Accounts Payable, Current Debt conversion fee equal to amount of principal outstanding, percentage Debt Instrument, Debt Conversion Fee Equal To Principal Amount Outstanding, Percentage Debt Instrument, Debt Conversion Fee Equal To Principal Amount Outstanding, Percentage Contract with customer, liabilities, revenue recognized Contract with Customer, Liability, Revenue Recognized Retained earnings Retained Earnings [Member] 2.500% Senior Notes due 2030 2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) 2.5% Senior Notes Due 2030 [Member] 2.5% Senior Notes Due 2030 [Member] Revolving credit facility Revolving Credit Facility [Member] Consolidated Leverage Ratio to be maintained Debt Instrument, Covenant, Consolidated Leverage Ratio, Maximum Debt Instrument, Covenant, Consolidated Leverage Ratio, Maximum Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Carrying Amounts and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Diluted (in usd per share) Earnings Per Share, Diluted Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity current reporting status Entity Current Reporting Status Total cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation 2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”) 2.6% Senior Unsecured Notes Due 2029 [Member] 2.6% Senior Unsecured Notes Due 2029 [Member] Total Shareholder Return Amount Total Shareholder Return Amount Change in prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Cash flow hedges Cash Flow Hedging [Member] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Unrealized investment gains (losses) Unrealized Gain (Loss) on Investments Litigation Case [Domain] Litigation Case [Domain] Net proceeds from (repayments of) borrowings (maturities of 90 days or less) Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less Amortization of intangible assets Amortization of intangible assets Intangible Asset, Finite-Lived, Amortization Expense Pro Forma Financial Information Business Combination, Pro Forma Information [Table Text Block] Research and development expenses Research and Development Expense Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Income tax impact Reclassification from AOCI, Current Period, Tax Business Combination, Pro Forma Information, Nonrecurring Adjustment [Domain] Business Combination, Pro Forma Information, Nonrecurring Adjustment [Domain] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Sales Revenue from Contract with Customer, Excluding Assessed Tax Property, plant and equipment, net of accumulated depreciation of $4,915 and $4,767, respectively Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Financial Instruments [Domain] Financial Instruments [Domain] Derivative assets Derivative Asset 3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”) 3.4% Senior Unsecured Notes Due 2049 [Member] 3.4% Senior Unsecured Notes Due 2049 [Member] Debt Rate, Condition Two Debt Rate, Condition Two [Member] Debt Rate, Condition Two Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] Long-term tax liabilities Deferred Income Taxes and Other Tax Liabilities, Noncurrent Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Goodwill and Other Intangible Assets Intangible Asset and Goodwill [Text Block] Underlying Securities Award Underlying Securities Amount Fair Value Estimate of Fair Value Measurement [Member] Revenue Revenue from Contract with Customer [Text Block] 2025 Repurchase Program 2025 Repurchase Program [Member] 2025 Repurchase Program Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Cross-currency swap derivative contracts Foreign Currency Contracts, Liability, Fair Value Disclosure Prepaid expense Prepaid Expense, Current Utility Patent Utility Patent [Member] Utility Patent All other investing activities Payment for (Proceeds from) Other Investing Activity Change in inventories Increase (Decrease) in Inventories Excise tax on stock repurchases Share Repurchase Program, Excise Tax Segment Reporting [Table] Segment Reporting [Table] Weighted average interest rate of long-term debt, interest rate Long-Term Debt, Weighted Average Interest Rate, at Point in Time Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Operating profit Operating Income (Loss) Revenue, remaining performance obligation Revenue, Remaining Performance Obligation, Amount Current fiscal year end date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Acquisitions Business Combination [Text Block] Impairment charges, after tax Asset Impairment Charges, Net Of Taxes Asset Impairment Charges, Net Of Taxes Diagnostics Diagnostics Segment [Member] Diagnostics Segment Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity file number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Notional Amount Outstanding Derivative and Nonderivative, Notional Amount Derivative and Nonderivative, Notional Amount 1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) 1.125% Bonds Due 2028 [Member] 1.125% Bonds Due 2028 [Member] Common stock-based award activity Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Impairment charges Impairments Asset, Impairment Loss Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Life Sciences Life Sciences Segment [Member] Life Sciences Segment Entity Information [Line Items] Entity Information [Line Items] Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Change in trade accounts receivable, net Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Cash income tax payments Income Tax Paid, after Refund Received Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Entity interactive data current Entity Interactive Data Current Long-term debt Long-Term Debt [Member] Variable Rate [Axis] Variable Rate [Axis] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity small business Entity Small Business Notes payable and current portion of long-term debt Debt, Current [Member] Debt, Current Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Property, Plant, and Equipment [Line Items] Property, Plant, and Equipment [Line Items] Number of shares remaining available for repurchases (in shares) Share Repurchase Program, Remaining Authorized, Number of Shares Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Other intangible assets, primarily technology, customer relationships and trade names Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived Federal statutory income tax rate, percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Pension and postretirement plan benefit adjustments Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Design Patent Design Patent [Member] Design Patent Other long-term assets Other Assets, Noncurrent Document type Document Type Cash paid for acquisitions Cash paid for acquisition Net cash consideration Payments to Acquire Businesses, Net of Cash Acquired Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Accrued expenses and other liabilities Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Issue Price (as % of Principal Amount) Debt Instrument, Redemption Price, Percentage Number of patents allegedly infringed Loss Contingency, Patents Allegedly Infringed, Number Goodwill [Table] Goodwill [Table] Litigation settlement, amount awarded from other party Litigation Settlement, Amount Awarded from Other Party 0.750% Senior Notes due 2031 0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) 0.75% Senior Notes Due September 2031 [Member] 0.75% Senior Notes Due 2031 [Member] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local phone number Local Phone Number Euro-denominated commercial paper (€4.1 billion and €933 million, respectively) 2026 Biopharma Euronotes 0.2% Senior Notes Due 2026 [Member] 0.2% Senior Notes Due 2026 [Member] Consolidation Items [Axis] Consolidation Items [Axis] Entity address, postal zip code Entity Address, Postal Zip Code Entity registrant name Entity Registrant Name Net investment hedges Net Investment Hedging [Member] Bonds Bonds [Member] Earnings before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Debt Rate Condition [Axis] Debt Rate Condition [Axis] Debt Rate Condition 1.65% senior unsecured bonds due 6/3/2031 (CHF 120 million) (the “2031 CHF Bonds”) 2031 CHF Notes 1.65% Senior Notes Due June 2031 CHF Notes [Member] 1.65% Senior Notes Due June 2031 CHF Notes Employment agreement, severance benefits sought value of shares (in shares) Employment Agreement, Equity Awards, Shares Employment Agreement, Equity Awards, Shares Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Income Tax Contingency [Table] Income Tax Contingency [Table] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Total Masimo Financing Euronotes Masimo Financing Euronotes [Member] Masimo Financing Euronotes Goodwill [Roll Forward] Goodwill [Roll Forward] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Trade Names Trade Names [Member] Financial Assets and Liabilities Carried at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total inventories Inventory, Net Award Type [Domain] Award Type [Domain] Revenue, OTLs and STLs Operating-type Lease And Sales-type Lease, Revenues Amount of operating-type lease and sales-type lease revenues. Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair Value Measurements Fair Value Disclosures [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Supplemental disclosures: Supplemental Cash Flow Information [Abstract] Weighted average maturity of long-term debt, at point in time Long-term Debt, Weighted Average Maturity, at Point in Time Long-term Debt, Weighted Average Maturity, at Point in Time Shares repurchased (approximately) (in shares) Treasury Stock, Shares, Acquired Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] PEO Name PEO Name Geographical [Axis] Geographical [Axis] Contract with customer, liabilities Contract with Customer, Liability Cash Flow Hedge Adjustments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Multi-year Credit Facility Third Amended And Restated Multiyear Credit Facility [Member] Third Amended And Restated Multiyear Credit Facility Debt obligations: Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Long-Lived Asset, Class [Axis] Long-Lived Asset, Class [Axis] Other segment items Segment Reporting, Other Segment Item, Amount Amortization of acquisition-related inventory fair value step-up Amortization Of Inventory Step Up Amortization Of Inventory Step Up Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity tax identification number Entity Tax Identification Number Income tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit Other components of net periodic benefit costs Other Nonoperating Income, Net Pension and Postretirement Benefits Amount of net pension and postretirement benefits classified as other income. Repurchase of common stock, including excise taxes Repurchases of common stock (approximately) Treasury Stock, Value, Acquired, Cost Method Cash and equivalents Beginning balance of cash and equivalents Ending balance of cash and equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Change in trade accounts payable Increase (Decrease) in Accounts Payable Entity incorporation, state code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Reporting Unit [Domain] Reporting Unit [Domain] Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets And Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets And Liabilities, Net Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Borrowings (maturities longer than 90 days) Proceeds from Debt, Maturing in More than Three Months Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] 0.4773% senior unsecured bonds due 4/9/2027 (CHF 250 million) (the “2027 CHF Bonds”)(f) 0.4773% 2027 CHF Notes [Member] 0.4773% 2027 CHF Notes Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Schedule of Derivative and Non Derivative Instruments in Consolidated Condensed Balance Sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Basic (in usd per share) Earnings Per Share, Basic Components of Stock-Based Compensation Program Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Net tax impact, amount Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Payments for repurchase of common stock Payments for Repurchase of Common Stock Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Notes payable and current portion of long-term debt Short-Term Debt, Fair Value Derivative Instruments, Gain (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Long-term debt Long-term debt Borrowings outstanding Long-Term Debt, Excluding Current Maturities Award Type [Axis] Award Type [Axis] 2024 Repurchase Program 2024 Repurchase Program [Member] 2024 Repurchase Program Willow Laboratories, Inc. Arbitration Willow Laboratories, Inc. Arbitration [Member] Willow Laboratories, Inc. Arbitration Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Trade accounts receivable, less allowance for doubtful accounts of $121 and $114, respectively Accounts Receivable, after Allowance for Credit Loss, Current Retained earnings Retained Earnings (Accumulated Deficit) Segment Reporting, Measurement Disclosures [Abstract] Product and Service [Axis] Product and Service [Axis] Investment in equity securities Equity Securities, FV-NI 2.50% senior unsecured bonds due 6/3/2056 (CHF 382 million) (the 2056 CHF Bonds”) 2056 CHF Notes 2.50% Senior Notes Due June 2056 [Member] 2.50% Senior Notes Due June 2056 2.25% senior unsecured bonds due 6/3/2038 (CHF 373 million) (the “2038 CHF Bonds”) 2038 CHF Notes 2.25% Senior Notes Due June 2038 [Member] 2.25% Senior Notes Due June 2038 Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Number of reporting units Goodwill, Reporting Unit, Number Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common stock Common stock Common Stock [Member] Gain on sale of product line Pretax gain on sale of product lines Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Fair Value Measurement [Domain] Fair Value Measurement [Domain] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] General Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Cover [Abstract] Cover [Abstract] Derivative Contract [Domain] Derivative Contract [Domain] 0.450% Senior Notes due 2028 0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) 0.45% Senior Notes Due 2028 [Member] 0.45% Senior Notes Due 2028 [Member] Foreign currency translation and other Goodwill, Foreign Currency Translation, Gain (Loss) Equity Awards Adjustments Equity Awards Adjustments [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Hedging Relationship [Domain] Hedging Relationship [Domain] Total liabilities and stockholders’ equity Liabilities and Equity Realized investment gains (losses) Realized Investment Gains (Losses) Stock options Share-Based Payment Arrangement, Option [Member] Notes payable and current portion of long-term debt Less: currently payable Debt, Current Amounts Reclassified from OCI Increase (decrease) Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] 0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) 0.3% Senior Notes Due 2027 [Member] 0.3% Senior Unsecured Notes Due 2027 [Member] Cash flow and net investment hedges Cash Flow and Net Investment Hedges [Member] Cash Flow and Net Investment Hedges Summary of Effective Income Tax Rate Summary Of Effective Income Tax Rate [Table Text Block] Summary Of Danaher's Effective Income Tax Rate Income Tax Authority [Domain] Income Tax Jurisdiction [Domain] Tabular List, Table Tabular List [Table Text Block] Other income (expense), net Total other income (expense), net Other Nonoperating Income (Expense) Name Awards Close in Time to MNPI Disclosures, Individual Name Stockholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Payments for purchases of investments Payments to Acquire Investments Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] 1.350% Senior Notes due 2039 1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) 1.35% Senior Notes Due 2039 [Member] 1.35% Senior Notes Due 2039 [Member] Long-Lived Asset, Class [Domain] Long-Lived Asset, Class [Domain] 1.800% Senior Notes due 2049 1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) 1.8% Senior Notes Due September 2049 [Member] 1.8% Senior Notes Due 2049 [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Share Repurchase Program Share Repurchase Program [Table Text Block] Share Repurchase Program Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Table] Foreign currency denominated debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated debt [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] (Payments for) proceeds from the issuance of common stock in connection with stock-based compensation, net Payments For Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Payments For Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Reclassification adjustments, net of income taxes Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Number of complaints Loss Contingency, Pending Claims, Number Change in accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Share Repurchase Program [Axis] Share Repurchase Program [Axis] Class of Stock [Domain] Class of Stock [Domain] Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash interest payments Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Gain (Loss) Recognized in OCI Other Comprehensive Income Unrealized Gain Loss On Derivatives And Nonderivatives Arising During Period Before Tax Other Comprehensive Income Unrealized Gain Loss On Derivatives And Nonderivatives Arising During Period Before Tax Summary of Share Activity Schedule of Stock by Class [Table Text Block] Credit Facility [Axis] Credit Facility [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Income Tax Authority [Axis] Income Tax Jurisdiction [Axis] Name Measure Name 364-Day Facility 364-Day Facility [Member] 364-Day Facility Income Taxes Income Tax Disclosure [Text Block] Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Euro-Denominated Commercial Paper [Member] Euro-denominated commercial paper Euro-Denominated Commercial Paper [Member] Euro-Denominated Commercial Paper [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional paid-in capital Additional Paid-in Capital [Member] Entity filer category Entity Filer Category Intangible Asset, Indefinite-Lived, Class [Axis] Intangible Asset, Indefinite-Lived, Class [Axis] 2.38% senior unsecured bonds due 6/3/2041 (CHF 648 million) (the “2041 CHF Bonds”) 2041 CHF Notes 2.38% Senior Notes Due June 2041 CHF Notes [Member] 2.38% Senior Notes Due June 2041 CHF Notes Goodwill, impairment loss Goodwill, Impairment Loss Name Trading Arrangement, Individual Name Raw materials Inventory, Raw Materials, Net of Reserves Company Selected Measure Amount Company Selected Measure Amount Taxes receivable Income Taxes Receivable Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Common stock-based compensation awards Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Stock, Class of Stock [Table] Stock, Class of Stock [Table] Net tax impact, percent Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent Acquisition, price per share (in usd per share) Business Combination, Price Per Share 2034 Euronotes 3.625% senior unsecured notes due 4/29/2034 (€750 million) (the “2034 Euronotes”) 3.625% Senior Notes Due April 2034 Euro Notes [Member] 3.625% Senior Notes Due April 2034 Euro Notes Current assets: Assets, Current [Abstract] Derivative liabilities Derivative Liability Sales Business Combination, Pro Forma Information, Pro Forma Revenue Non-PEO NEO Non-PEO NEO [Member] Senior notes Senior Notes [Member] Entity address, address line one Entity Address, Address Line One North America North America [Member] Income taxes Income Tax Expense (Benefit) Other Income (Expense), Net Other Income and Other Expense Disclosure [Text Block] Noncash items: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract] Cost of sales Cost of Product and Service Sold Award Timing Method Award Timing Method [Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Net change in cash and equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Deferred tax liabilities Business Combination, Recognized Liability Assumed, Deferred Tax Liability 2.10% senior unsecured bonds due 6/3/2036 (CHF 221 million) (the 2036 CHF Bonds”) 2036 CHF Notes 2.10% Senior Notes Due June 2036 CHF Notes [Member] 2.10% Senior Notes Due June 2036 CHF Notes Net earnings Net earnings Net earnings Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Proceeds from sales of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Statement [Table] Statement [Table] Debt Rate Condition [Domain] Debt Rate Condition [Domain] Debt Rate Condition [Domain] Restatement Determination Date: Restatement Determination Date [Axis] Components of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Interest income Investment Income, Interest Operating Leases Lessee, Leases [Policy Text Block] Fed funds rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Derivative, original notional amount Derivative, Original Notional Amount Derivative, Original Notional Amount Prepaid Expenses and Other Current Assets Prepaid Expenses And Other Current Assets [Policy Text Block] Prepaid Expenses And Other Current Assets Net investment hedges, gain (loss), recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Damages sought, value Loss Contingency, Damages Sought, Value Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract]